An Investor Shows Interest in Kali Inc (OTCMKTS:KALY) ‘s Cannabis Extract Biopharmaceutical Technology: Kali Confirms Acquisition Interest

An Investor Shows Interest in Kali Inc (OTCMKTS:KALY) ‘s Cannabis Extract Biopharmaceutical Technology: Kali Confirms Acquisition Interest

Kali
Inc (OTCMKTS:KALY)
doing
business as kali Extracts has confirmed an investor’s acquisition interest in
its Cannabis Extract Biopharmaceutical Technology. Chief Executive Officer of
Kali, Frederick Ferri, said interest in its Cannabis Extract Biopharmaceutical
Technology from an investor shows that its technology is undervalued. The
company would release an update on acquisition interest on October 30, 2019.

Kali
takes over NCMB in Q4 2018

Kali has taken over NCMB, which
operates the patented cannabis extraction process in Q4 2018. Before acquired
by Kali, NCMB is a leading player in developing plant-derived cannabinoid
therapeutics with the help of the patented development process in its four
years of operation. The manufacturing expertise, the established regulatory
framework, and an intellectual property portfolio are the result of NCMB’s
four-year operation.

Market
for COPD

The market for chronic obstructive
pulmonary disease (COPD) would touch $14 billion by the year 2025. Demand for
Type 2 diabetes treatment is expected to reach $64 billion by the year 2026.
The market for overall pain management is forecasted to reach $83 billion by
the year 2024. Kali would supply CBD products for the treatment of these
diseases.

Kali has filed a patent for a new formulation for the
treatment of COPD symptoms. The company also applied for the trademark
‘RespRx,’ a brand name for the CBD formulation to treat COPD symptoms and other
respiratory conditions. Kali is at an advantage with its new formulations for
COPD cure.

To comply with US FDA requirements, Kali is in the
process of getting its proprietary extracts, which are derived from the
US-patented extraction process, certified. Kali has established substantial
achievements since the update of the biopharmaceuticals strategy. The company
associated with a major university to test and evaluate COPD treatment
formulations. It will soon kickoff this evaluation process and issues an update
at a later date. Advances made in the treatments helped Kali to establish new
partnerships. The company would issue an update on new partnerships.

Puration Inc has obtained a limited license for the
patented process of Kali to infuse cannabis extracts in its beverages. Kali is
also marketing CBD infused candies under its brand name – Hemp4mula.

Published at Mon, 28 Oct 2019 12:14:05 +0000

Be the first to comment

Leave a Reply

Your email address will not be published.


*